Skip to main content
Equibles
ELV logo

ELV · Elevance Health, Inc. · Metrics

Track ELV — free

Use ELV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$450.00 +9.82 (+2.23%) Earnings today
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$95.46B
Shares
216.87M
Volume · Oct 20 1.55M Avg daily vol (3M) 1.13M

ELV metrics

115 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$440.18
Market cap
$95.46B

Price action

20 metrics
Price change (1W)
+3.5%
Price change (30D)
+7.5%
Price change (3M)
+11.9%
Price change (6M)
+34.2%
Price change (YTD)
+25.6%
Price change (1Y)
+24.3%
Trailing year
Price change (5Y)
+3.8%
52-week high
$440.18
52-week low
$280.74
Change from 52-week high
+0.0%
Change from 52-week low
+56.8%
Annualized volatility
35.0%
Annualized volatility (3M)
24.8%
Beta
0.3
RSI (14D)
73.0
Price vs SMA 50
+8.6%
Price vs SMA 200
+19.0%
Avg volume (3M)
1.13M
Relative volume
1.4
Average dollar volume
$454.21M

Company

3 metrics
Sector
Healthcare
Industry
Healthcare Plans
Shares outstanding
216.87M

Valuation

12 metrics
P / E (TTM)
19.5
Trailing earnings · reciprocal yield 5.1%
PEG ratio
—
EV / revenue
0.6×
reciprocal yield 173.0%
EV / EBITDA
16.7×
reciprocal yield 6.0%
EV / EBIT
21.3×
reciprocal yield 4.7%
P / sales
0.5×
reciprocal yield 210.7%
P / book
2.1
reciprocal yield 47.0%
FCF yield
6.6%
TTM · current market cap
Buyback yield
2.8%
P / FCF
15.2
reciprocal yield 6.6%
P / operating cash flow
12.8
reciprocal yield 7.8%
Earnings yield
5.2%

Historical valuation

8 metrics
P / E historical average (3Y)
16.4×
reciprocal yield 6.1%
P / E historical average (5Y)
17.6×
reciprocal yield 5.7%
EV / revenue historical average (3Y)
0.6×
reciprocal yield 155.7%
EV / revenue historical average (5Y)
0.7×
reciprocal yield 136.7%
EV / EBIT historical average (3Y)
14.8×
reciprocal yield 6.7%
EV / EBIT historical average (5Y)
15.7×
reciprocal yield 6.4%
EV / EBITDA historical average (3Y)
12.4×
reciprocal yield 8.1%
EV / EBITDA historical average (5Y)
13.1×
reciprocal yield 7.6%

Dividends & buybacks

7 metrics
Dividend yield
1.6%
Trailing 12 months
Payout ratio
30.3%
Shareholder yield
4.4%
Dividend / share (TTM)
$6.87
Dividend growth YoY
+1.6%
Dividend growth streak
5+
Stored dividend history starts 2020
Last ex-dividend
2026-09-10

Earnings calendar

2 metrics
Next earnings
2026-10-21
Last earnings
2026-07-15

Profitability

9 metrics
Gross margin
89.1%
Operating margin
2.7%
Trailing 12 months
Net margin
2.5%
Gross profit (TTM)
$179.26B
Operating profit (TTM)
$5.45B
Net income (TTM)
$4.96B
Trailing 12 months
Diluted EPS (TTM)
$22.59
FCF margin
3.1%
Effective tax rate
15.6%

Per share

11 metrics
Revenue per diluted share (TTM)
$910.33
Gross profit per diluted share (TTM)
$811.39
Operating profit per diluted share (TTM)
$24.74
EBITDA per diluted share (TTM)
$31.58
Net income per diluted share (TTM)
$22.49
Operating cash flow per diluted share (TTM)
$33.89
Free cash flow per diluted share (TTM)
$28.57
Capital expenditures per diluted share (TTM)
$5.31
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$1.10
Book value per share
$198.81

Growth

11 metrics
Revenue growth YoY
+1.4%
Year over year
Net income growth YoY
-16.1%
Revenue (TTM)
$201.11B
Trailing 12 months
EPS growth YoY
-13.1%
Shares change YoY
-3.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+8.3%
Revenue CAGR (5Y)
+10.3%
EPS CAGR (3Y)
+1.3%
EPS CAGR (5Y)
+7.0%
FCF CAGR (3Y)
-24.1%
FCF CAGR (5Y)
-20.0%

Quality

14 metrics
Return on equity
11.1%
Return on assets
3.9%
Debt / equity
0.7
Current ratio
1.5
EBITDA (TTM)
$6.97B
Free cash flow (TTM)
$6.29B
Quick ratio
1.5
Interest coverage
3.8
Net debt / EBITDA
3.0
Return on invested capital
7.0%
Trailing 12 months
Net cash
−$20.81B
Latest balance sheet
Cash & equivalents
$10.23B
Total assets
$126.44B
Total debt
$31.04B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$7.46B
Capital expenditures (TTM)
$1.18B
R&D (TTM)
—
SG&A (TTM)
$22.56B
Stock compensation (TTM)
$244.00M
R&D / revenue
—
Stock compensation / revenue
0.1%

Ownership (13F)

9 metrics
13F filers
1,625
13F filer change QoQ
+148
Institutional ownership
92.9%
Conviction holders (share of 13F filers)
1.7%
Crowding (high-turnover and private-fund holders)
24.4%
Private-fund adviser ownership
23.8%
Active holders' share change QoQ
+1.9%
Holder tenure
18.6
Price vs estimated holder cost
+2.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.7%

Short interest

3 metrics
Short interest
2.2%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1156039 CUSIP 036752103 13F (30d) 324 filings 296 filers Visit website Investor relations